An Early Phase 1 interventional study of Ursodiol 500 MG in Clostridioides Difficile Infection, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Medical College of Wisconsin · Early Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 121 studies in Clostridium Infections with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Clostridium Infections · United States.
Among the 121 studies in Clostridium Infections with a site in United States, this one is the 64th largest by planned enrollment of the 102 interventional ones that give a count, is one of 6 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 13 of the 18 other live ones, and was the 114th registered.
251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.
Browse Clostridium Infections studies →16 of the 121 studies in Clostridium Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–75 · Healthy volunteers
Acurx Pharmaceuticals Inc. · Sites in United States
Ages 18–90
University of Michigan · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Australia, Canada and 11 more countries
Ages 18+
Riverside University Health System Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 36 Clostridium Infections studies recruiting now, 22 (61%) set no upper age limit and 8 (22%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
121 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 40 · Phase 3 21 · Phase 4 14
First in 1998; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 64 across 185 interventional studies indexed under Clostridium Infections.
Median enrollment 57 across the 102 interventional studies, 132 across the 19 observational. Of the 91 that completed or were terminated, 52 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 121 have an industry lead sponsor. The 10 most frequent:
Medical College of Wisconsin is the lead sponsor of 550 studies on the registry; 123 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 58 (76%) have results posted.
Medical College of Wisconsin has 4 studies filed under Clostridium Infections — fewer than ten, so there is no comparison to draw.
7 of the studies in Clostridium Infections with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221370Phase 3Riverside University Health System Medical CenterEnteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients | 2026-12-31 |
| NCT06237452Phase 3Vedanta Biosciences, Inc.VE303 for Prevention of Recurrent Clostridioides Difficile Infection | 2027-06 |
| NCT04305769University of VirginiaAlanyl-glutamine Supplementation for C. Difficile Treatment (ACT) | 2026-12-31 |
| NCT07250724Bactolife A/SC. Difficile Toxin Levels in Stool From Healthy Individuals Following Standard of Care Antibiotic Treatment for CDI. | 2027-01-15 |
| NCT07285213AstraZenecaPrevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody | 2027-04-20 |
Add all 7 to your calendar (.ics) → With an account.
Among the 121 studies in Clostridium Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether Ursodeoxycholic Acid (UDCA) can help prevent recurrence of Clostridioides difficile (C. diff) colitis when used along with standard antibiotic treatment. C. diff colitis is a serious infection that can return after treatment, and researchers want to see if UDCA can reduce this risk.
This study aims to answer three main questions. First, can UDCA help prevent C. diff from returning after standard treatment? Second, does adding UDCA to treatment lower the need for repeated antibiotic use? Third, is UDCA safe and well-tolerated for people with C. diff?
Participants in the study will be adults diagnosed with C. diff colitis who have risk factors for recurrence. Each participant will receive standard antibiotic treatment, which may include Vancomycin, Fidaxomicin, or Metronidazole. In addition to their antibiotic therapy, participants will take UDCA at a dose of 500 mg three times a day for up to eight weeks. If a participant's stool test shows they are C. diff negative at four weeks, they will stop taking UDCA early.
Researchers will monitor participants throughout the study. Stool samples will be tested at the beginning, after four weeks, and at the end of the study. If a participant develops diarrhea, a stool test will check for C. diff. If C. diff is negative, the UDCA dose will be reduced. Weekly phone calls will be made to check for side effects and ensure participants are following the treatment plan.
C. diff colitis is a common and serious infection, with up to 46 percent of high-risk patients experiencing recurrence. Current treatments rely on antibiotics, which can disrupt gut bacteria and increase the risk of reinfection. UDCA is a naturally occurring bile acid that may help prevent C. diff from growing, reducing the need for repeated antibiotic treatment. If successful, this study could introduce a new way to prevent C. diff from coming back, helping patients recover more effectively while reducing antibiotic use.
Eligible participants must be at least 18 years old, have a positive C. diff test, and be receiving standard antibiotic treatment for C. diff. People who have severe or life-threatening C. diff colitis, a life expectancy of less than six months, serious liver disease, or are pregnant or breastfeeding will not be eligible to participate.
UDCA is FDA-approved and has been used safely for decades in liver diseases and gallstone treatment. Some people may experience mild side effects, such as diarrhea, nausea, or stomach discomfort. Participants will be closely monitored for safety throughout the study.
This trial will take place within the Froedtert and Medical College of Wisconsin healthcare system in Milwaukee, Wisconsin.
Prevention of Recurrence of Clostridioides Difficile Colitis with
Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy
Paraj D. Patel M.D, Daniel J. Stein, M.D, Helmut V. Ammon, MD
This proposal describes the use of UDCA as an adjunct to standard treatment of C. difficile (C. diff) colitis for the prevention of recurrence of the disease.
The Problem: C. diff colitis is a serious burden on the healthcare system. In 2011 there were close to 500,000 cases of and 29,000 deaths from C. diff. colitis reported in the US at an annual cost of 58 billion dollars [1, 2] Treatment consists of Vancomycin or Fidaxomicin [3]. The recurrence rate is between 7% and 20% within 2 months [1, 4]. The risk of recurrence increases with each episode and various risk factors to up to 46% in the presence of more than 3 risk factors[5, 6]. Current efforts to deal with this problem include prolonged treatment with antibiotics, fecal microbiota transplants, probiotics, and monoclonal antibodies [7] .
Recurrent C. diff. infection is associated with is a loss of diversity in the fecal microbiome and the consequent loss of the ability to deconjugate bile acids [6, 8]. Stool from patients with recurrent C. diff. colitis requiring fecal transplant contains mainly taurocholate and no secondary bile acids [9]. In in vitro studies taurocholate facilitates the germination of C. difficile spores and the growth of the vegetative form [10]. For this reason, taurocholate is used in the growth medium for the culture of C. diff [9]. Treatment of recurrent C. diff. colitis with fecal transplants is directed at restoration of the diversity of the fecal microbiome and restoration of a normal fecal bile acid profile [3, 11, 12]
The Solution:
UDCA, a secondary bile acid derived from chenodeoxycholic acid in the human colon, inhibits the germination of C. diff in vitro at a and its growth of the vegetative form in concentration as low as 0.5 mmol/L [13, 14]
This observation prompted the use of UDCA (1200 mg/day) for the successful treatment of a patient with an ileo-anal pouch with recurrent intractable C. difficile pouchitis [14]. A subsequent uncontrolled case series reported the successful control of recurrent C. difficile colitis in 14 out of 16 patients with UDCA (600 - 900 mg/day) given for 29 - 235 days[15].
Three different studies using different experimental designs indicate that UDCA is poorly absorbed and that adequate doses of UDCA could deliver adequate colonic concentrations to prevent germination and inhibit growth of C. difficile [16-18]
Experimental Design and Calculation of Sample size
We assume that a higher dose of UDCA (1500 mg/day) could improve the results observed by Webb et al [15]. Assuming a fecal weight of 400g/day (diarrhea) with the corresponding volume of distribution of 400 ml the patients in the study by Webb et al [14] would have had a fecal concentration of UDCA of 1.8 mmol/L, based on the absorption rates observed by Walker et al [17]. The dose of UDCA in our proposal (1500 mg/day) would result in a fecal UDCA concentration of 7 mmol/L, well above the 0.5 mmol/l inhibiting vegetative growth of C. diff in vitro [11,12]
For the exploratory study we propose to use a single arm, open label design with historical controls. Use of historical controls is justified if the study population is small, as in our single center study, and the outcome in question is dichotomous [19].
As historical controls we will use the placebo group of the treatment trial of the use of Bezlutoxumab for the prevention of the recurrence of C. difficile colitis [7]. Using patients with ≥1 risk factors we would get a sample size in the control group of n = 468 with a recurrence rate of 37.2 %. Since the outcome is dichotomous (Recurrence yes/no) we used the ClinCalc sample size calculator to determine the necessary Number to Treat. Assuming a 12.5% recurrence rate for a minimal response [13] the necessary Number to Treat is 25 (plus 2 to account for drop-outs) (for Type I/II error: Alpha 0.05; Beta 0.2; Power 0.8). In the study the proposed dose of UDCA will be 1500 mg/day (approximately 20 mg/kg/day) in divided doses. The dose was chosen to get adequate colonic concentrations of UDCA while reducing the risk of drug induced diarrhea [18-22]. The duration of treatment will be 60 days, the time interval for most recurrences to occur [1, 3].
Safety:
UDCA has been widely used for the dissolution of gallstones prior to the advent of laparoscopic cholecystectomy [20] and is currently the FDA approved treatment of choice for Primary Biliary Cholangitis (PBC)[21]. It is the treatment of choice for cholestasis of pregnancy (ICP)[22], and for the prevention of gallstone formation after gastric bypass surgery [23]. It is also being used for treatment of primary sclerosing cholangitis (PSC) [24], liver disease due to cystic fibrosis [25], and for the prevention of hepatic complications in allogenic stem cell transplantation [26].
The safety of the administration of UDCA as high as 30 mg/kg/24 hours (50 % higher than in our proposal) is well established. Nine studies report the use of UCDA 28-35 mg/kg/day for weeks to 3 years in treatment trials in 378 patients, 74 with PBC [27, 28], 115 with PSC [29-31], 169 with nonalcoholic steato-hepatitis (NASH)[32-34], and 20 with ICP [22]
Only one study of patients with NASH reports significant side effects (diarrhea in 38.7% vs. 17.2 % in the placebo group (p\<0.01) and abdominal discomfort in 25.8% vs. 10.9% (p\<0.04) [34]. One study of 12 patients with NASH reported diarrhea in 2 and fatigue and pruritus in 1 [33]. One study of 54 patients with PBC reports 2 cases with diarrhea, 2 with nausea and vomiting, 1 with thrombocytopenia, and 1 with a skin rash [27]. In a study of patients with NASH 11/95 patients receiving UDCA developed diarrhea vs 1/91 in the placebo group [32]. In a study of 10 patients with PSC receiving high dose UDCA one developed cholangitis, 1 underwent cholecystectomy and 1 reported loss of libido [29]. The largest study of the use of high dose UDCA in PSC was terminated after three years because of a higher incidence of adverse effect on outcomes of the liver disease in comparison to the placebo group [31]. A retrospective analysis of this study also found a higher incidence of neoplastic changes in the colon in patients with chronic ulcerative colitis in comparison with the control group after 2 years of therapy [35]. Taking all studies together 17.9 % of patients receiving high dose UDCA developed diarrhea. A systematic review of the literature found no serious side effects with the use of UDCA [36]
We therefore feel justified to test the ability of UDCA administered at a dose of 1500 mg/day in divided doses (approximately 20 mg/kg/day) to prevent the recurrence of C. difficile colitis in a pilot program, enrolling consecutive patients and comparing the outcome to historical controls.
PROTOCOL
.
Eligible patients: C. diff. toxin +ve patients > 18 years with one or more risk factors for recurrence [6,7] requiring standard treatment with Flagyl, Vancomycin or fidaxomicin.
Exclusion criteria: Life expectancy \< 6 months; fulminant colitis; ileus; decompensated liver disease; pregnancy and lactating females; Inability to give informed consent.
Treatment: Standard treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID. UDCA to be started while patient is on antibiotics for C. diff. for 8 weeks (unless C. diff negative by 4 weeks).
Follow-up for 6 moths.
Endpoint: Relapse yes/no
Monitoring:
Check stool for C. diff (PCR/toxin) at entry, at 4 weeks, and at completion. If C. diff negative by 4 weeks stop treatment. If patient reports diarrhea, check stool for C. diff. toxin. If negative, reduce UDCA by 25%.
Weekly telephone call to patient to check on side effects and encourage compliance
Ribotyping of C. diff at entry
Recruitment:
Potential patient pool: Patients within the Froedtert/MCW health care
system in the greater Milwaukee area
Lab issues daily list of C. diff positive patients
Obtain permission from PCP to contact patient,
Screen for exclusions,
Obtain informed consent,
Enroll patient,
Budget:
Number of patients: 27
Medication: Ursodeoxycholic acid 500 mg capsules: (n=4,860)
Pharmacy quote: $ 96.78/100 $ 4,704.--
Cost of stool test for C. difficile at 4 and 8 weeks
Cost for profiling of C. diff strains (ribotyping)
References
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard of care treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID for 8 weeks. UDCA to be started while patient is on antibiotics for C. difficile and continue for 8 weeks total.
Drug: Ursodiol 500 MG
Standard of care treatment (Flagyl, Vancomycin or Fidaxomicin) + UDCA 500 mg TID for 8 weeks. UDCA to be started while patient is on antibiotics for C. difficile and continue for 8 weeks total.
Lack of recurrent C. difficile recurrence
Absence of recurrent C. difficile recurrence based on symptoms and standard of care testing at 3 months and repeat stool testing at 8 weeks.
Time frame: 8 weeks and 3 months
Plan to share: Yes — De Identified participant information and results
Supporting information: Study protocol, Statistical analysis plan
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for May 2028, 22 months after the start.
Of 15 phase 1 interventional studies under Clostridium Infections, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 22 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start May 2026 → Jun 2026 and primary completion May 2027 → May 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ursodeoxycholic Acid
Medical College of Wisconsin →